Table III.
Percentage of subjects expressing h-TERT and h-TERC mRNA in lung tissue and BALF samples.
| A, Lung tissue samples | ||||
|---|---|---|---|---|
|
| ||||
| Control (n=21) | IPF (n=29) | NSCLC (n=10) | p-valuea | |
| h-TERT | 52.4% | 13.8% | 60% | p1=0.003 p2=NS p3=0.004 |
| h-TERC | 61.9% | 17.3% | 90% | p1=0.001 p2=NS p3=0.0001 |
|
| ||||
| B, BALF samples | ||||
|
| ||||
| Control (n=12) | IPF (n=23) | NSCLC (n=31) | p-valuea | |
|
| ||||
| h-TERT | 33% | 65.2% | 25.8% | p1=0.07 p2=NS p3=0.004 |
| h-TERC | 50% | 73.9% | 59.1% | p1, p2, p3=NS |
a
χ2 test, p<0.05 was considered to indicate a statistically significant difference.
NS, not significant p1, IPF vs. controls; p2, NSCLC vs. controls; p3, IPF vs. NSCLC. NSCLC, non-small cell lung cancer; IFP, idiopathic pulmonary fibrosis; BALF, bronchoalveolar lavage fluid.